

The Major Challenge between Immigration and Viral Hepatitis in Europe: Summary Review

Alsalih Nawar Jasim

Almuthana University, Iraq

Abstract: *Migration is affected by many factors combined of economic, political and social factors: either in the country of destination (Attractive factors or in a migrant's country of origin (Repellent factors)). Verifiably, the relative financial flourishing and political steadiness of the EU are thought to have applied an extensive draw impact on migrants, but this huge mass of migration imported the new challenge to the health care system to the Europe represented by hepatitis viral infection.*

Keywords: challenge; immigration; viral hepatitis; Europe; review

1. Immigration to Europe in statistics

Generally, the relative monetary thriving and political soundness of the EU are thought to have applied an extensive force impact on settlers, yet this colossal mass of relocation imported the new impact to the medicinal services framework to the European countries by hepatitis viral contamination[1]. Most migrants overall start from center salary nations (157 million in 2015). In the vicinity of 2000 and 2015, the quantity of vagrants starting from center pay nations expanded more quickly than those from nations in some other salary amass. The middle period of global vagrants worldwide was 39 years in 2015, a slight increment from 38 years in 2000. In 2015, 76 million universal transients were dwelling in Europe, contrasted with 75 million in Asia.

Today, Eastern European nations like Kosovo Albania still add to the general stream of haven searchers into the EU, Norway and Switzerland, however about portion of outcasts in 2015 follow their causes to only three nations: Afghanistan, republic of Iraq and Syria. Since 2012, Germany has been the essential goal nation for refuge searchers in Europe, getting 442,000 shelter applications in 2015 alone. The Germany, Hungary (174,000 applications) and Sweden (156,000) got the most surprising number of refuge applications in 2015. In the mean time, France (71,000) and the UK (39,000) got generally an indistinguishable number of utilizations in 2015 from in years only preceding the outcast surge in 2015[2]. The 2015 surge denoted the biggest yearly stream of shelter searchers to Europe since 1985. By correlation, the second biggest came in 1992, after the fall of the Berlin Wall, when 697 thousands linked for refuge to the countries that make up current EU nations, Switzerland and Norway [2].

2. Epidemiology of viral hepatitis in Europe

In the European Center for disease control and prevention (ECDC) systematic evaluation examine the prevalence of each hepatitis C and B infections at about 1% in my view in the countries of the European Union and European Economic Area. The prevalence of HCV is decided to be around 1.1% and of HBV round 0.9% in the EU/EEA, overall of 5.6 million HCV instances and 4.7 million HBV instances. Completely, international locations inside the eastern and southern part of the EU/EEA were discovered to have a higher HCV and HBV predominance than nations in the northern and western Europe. The HBV occurrence variety from one percent in Ireland to 4.4% in Romania, whilst the record observed that the prevalence of hostile to HCV ranges from 0.1% in Belgium, Ireland and the Netherlands, to 5.9% in Italy[3].

The incidence of hepatitis B surface antigen (HBsAg) within the fashionable populace varies extensively between European countries with intermediate to excessive HBsAg carrier rates in Turkey (8%) and Romania (6%), accompanied by means of Bulgaria (4%), Latvia (2%), and Greece (2%). In the Slovak Republic, Lithuania, Italy, Germany Poland, Czech Republic, and Belgium, the HBsAg prevalence became 0.5%-1.5% and within the Netherlands, Estonia, Norway, Slovenia, and Hungary under 0.5% (figure 1). The estimates are from exceptional years and populations, which makes assessment hard. Estonia is, however, taken into consideration to be a fantastically endemic country due to the excessive occurrence of cases (33/a hundred,000)[4].

In a late study the geographical vicinity of Europe as described by means of the WHO (i.e. Inclusive of the previous USSR republics) has estimated that the prevalence of HCV varies between 2.4% for Western and Central Europe and 2.9% for Eastern Europe. The worldwide population of this area is approximately 740,000,000 people, main to an estimation of the HCV infection pool of greater than 19,000,000 men and women[5] figure 2.




Figure 1: Rate of reported acute hepatitis B cases per 100 000 population EU/EEA 2014




Figure 2: Epidemiology of HCV in Europe (ECDC 2010)

In 2015, 12 527 showed hepatitis A cases had been said to the European Surveillance System (TESSy) by way of 30 EU/EEA international locations, Hepatitis A seroprevalence affords a excessive degree of temporal and spatial variability across the EU/EEA. There is an general reducing trend through the years in maximum countries and an important geographical increasing pattern of seroprevalence from northern to central, southern and eastern EU/EEA. Conversely, the susceptibility to infection among adults ranged among low (3 countries) to very high (five countries) with a marked south to north geographical susceptibility increase pattern[6].

In Europe, acute HEV infection is identified in 5 –15% of patients with acute hepatitis for whom hepatitis A–C have been ruled out [7][8]. Most patients with acute hepatitis E virus are migrants in endemic regions, or those who have

gone through transfusions; additionally they commonly consume pig meat or drink contaminated water. Over the past due ten years, the seroprevalence of anti-HEV IgG has been growing in European international locations and suggests full-size variability amongst distinct geographical areas. The primary research were achieved on the overall populace and on blood donors, and the high occurrence of HEV-RNA positive infection and anti-HEV antibody prevalence in blood donors amongst 1% and fifty two% suggests that HEV is responsible for numerous instances of subclinical HEV contamination in Europe[9][10]. In European international locations, as in other developed regions, values of seroprevalence towards HEV are difficult to interpret, possibly due to the lack of genotype-unique assays and the huge diversity of methods hired to discover antibodies in opposition to the virus, which range in sensitivity and specificity[11][12]. HEV seroprevalence

varies among European countries. Some values notified for general population are 13% in UK[13], 2.7% in Italy[14], 1.9% in Netherlands[15], 9.3% in Sweden[16], 16.8% in Germany[17], 1.5% in San Marino[18], and 7.3% in Spain[19]. Variations also are observed inside countries. Worldwide, it's far envisioned that 15–20 million people are HDV inflamed, with broadly varying occurrence, relying on the location [20]. It was long ago established that HDV is found throughout the world, with higher prevalence in countries with populations of low socioeconomic status in Africa and South America, as well as in Turkey, Mongolia, southern Italy, and the Soviet Union[21]. HDV antibodies were discovered in up to 30 % of chronic hepatitis B (CHB) patients in some of these nations[20]. In Europe, in which HDV had been notion to be lowering, studies in 2013 confirmed a trend closer to increasing incidence. The majority of HDV-infected patients have been both IV drug users and immigrants. In comparison, different European nations have been found to have extensively higher prevalence in some populations, with coinfection suggested in 20.4% of CHB sufferers in Bucharest, Romania, and 20.9 % of 1,220 CHB immigrants from Equatorial Guinea living in Spain[22][23].

3. Healthy background of immigrants and refugees coming to Europe

Some 6.8% of the population living in the EU in 2015 had been born outside of the EU, around 34.3 million people, even as the percentage in Russia (8.1%) changed into above the proportion inside the EU, in the United States (14.5%) it turned into more than twice as excessive as the share inside the EU[24].

The conflict in Syria is still via some distance the most important driver of migration. But the continuing violence in Afghanistan and Iraq, abuses in Eritrea, as well as poverty in Kosovo, are also main humans to search for new lives some place else, and in line with the Eurostat records Afghanistan, Syria and Iraq have been the primary institution of immigrant with greater than 500 000 immigrants looking for new host inside the Europe, observed through Kosovo, Albania, Pakistan, Eritrea, Nigeria, Iran, and Ukraine[24](fig.3). According to this assessment we listed the epidemiology of hepatitis in these countries.



Figure 3: Map of migration to the Europe

Limited occurrence statistics for, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) exist for Afghanistan. A cross-sectional research of samples of adults injection drug customers (IDUs) in Kabul, Afghanistan, from June 2005 via June 2006, had been found that the prevalences of HCV, and HBsAg have been 36.6% and 6.5% , respectively[25]. According to WHO 1804 hepatitis cases have been diagnosed and pronounced in 2015 – 1343 hepatitis B and 461 hepatitis C cases. However, the load of the disease is in all likelihood to be considerably higher. Another observe in Syria turned into found that the Low to low–intermediate levels of endemicity of hepatitis B and C infections were mentioned at the countrywide degree. However, hanging geographic differences and high prevalence amongst excessive-risk companies have been major[26].

A study was enrolled in Iraq of 69 915 blood donors, a complete of 1625 (2.3%) donors have shown serological proof for hepatitis B virus infection; of those donors, 125 (0.2%) confirmed a superb test result for both anti-HBc and

HBsAg at the same time as 1475 (2.1%) had wonderful anti-HBc effects because the only tremendous take a look at for HBV infection. The occurrence of anti-HCV changed into 0.1%[27].

Another research in Iraq become determined, a total of 7,576,372 consultations to primary health care facilities have been recorded in Baghdad. Among the ones a total of 2,692 instances (35.5 in step with 100,000 consultations) were categorised as acute viral hepatitis instances. A effective hepatitis viral marker (A, B, C and E) became found in 1,332 cases (17.6 in step with one hundred,000 consultations). More than two fifths (44.8%) of cases had been effective for anti-HAV antibodies and every other 1.6% had advantageous anti-HEV antibodies[28].

The study in Kosovo determined that the outcomes of sero-epidemiologic studies imply a high percent of HAV in the Kosovar populace, while the prevalence of HEV antibodies was low and similar to that of different European international locations. The HBV infection appears to be at

an intermediate degree of endemicity and immunization coverage towards HBV contamination, through vaccination of all newborns and children earlier than childhood, may be advisable. Results of this study suggest that the level of endemicity of HCV infection inside the Kosovar population is low[29]. The research done in Albania discovered that the results of sero-epidemiologic studies. Despite the expected -fold reduction of HBsAg occurrence in the widespread populace from about 18%-19% to 9.5%, Albania stays an extraordinarily endemic country (i.e. Over 8% of HBsAg occurrence rate). According to a study executed through Pakistan Medical Research Council in 2007-08, 7.6% Pakistani population suffered with hepatitis B and C, with round 4.8% with hepatitis C only. According to a few studies injecting drug customers have the best prevalence of hepatitis B and C in the country [30]. Pakistan is the country which has one of the maximum burdens of persistent hepatitis B and C and so excessive mortality because of liver failure and hepatocellular carcinoma. However, information approximately latest countrywide stage occurrence and chance elements is not available and one-of-a-kind research (clinic based totally and local) present exceptional prevalence rate inside the country [31].

According to a research achieved in Eritria for the duration of the 1998 discovered that the presence of HBsAg, indicating a high occurrence of hepatitis B provider reputes, became highest within the Guerrilla Fighters, accompanied by means of the Rashaidas (Participants from a tribe called Rashaida), and lowest in the Female Sex Workers[32]. Hepatitis B occurrence is highest in sub-Saharan Africa and East Asia, where between 5-10% of the person population is chronically infected, whilst with an occurrence of between 5-9% and an anticipated 32 million humans infected with the hepatitis C virus (HCV), sub-Saharan Africa has the highest burden of the disease in the global. Ultimately, Eritrea's vaccination programmes have played an important function in decreasing the prevalence and spread of hepatitis, and current research study estimate that the country's incidence of hepatitis B is approximately 2.49%, the lowest in Africa [33].

According to a new study performed in Nigeria for the duration of the 2015 discovered that the HBV infection is hyperendemic in Nigeria and may be the highest in Sub-Saharan Africa. These outcomes advocate that massive numbers of pregnant women and kids have been uncovered to HBV from 2000 to 2013[34].

Hepatitis B virus (HBV) prevalence has decreased dramatically in Iranian population during the last decade, and now Iran is classified as having low endemicity for hepatitis B infection in Iran, the prevalence of hepatitis C virus (HCV) contamination is noticeably low steady with the populace-based totally epidemiological studies. But a new study in Iran performed in 2015, discovered that the prevalence of HCV infection will boom in close to destiny not handiest among excessive-threat corporations but even inside the preferred population and blood donors of Iran[36].

4. The increasing burden of imported hepatitis infection on health care system in Europe

A global burden of disease study estimated that HEV genotypes 1 and 2 account for about 20.1 million incident HEV infections, 3.4 million instances of symptomatic disease, 70,000 deaths, and 3,000 stillbirths [37]. In developed countries, HEV infection in persons who receive immunosuppressive treatment following solid organ transplant is associated with risk of progression to chronic hepatitis E [38]. However, this phenomenon has now not been observed in developing countries wherein infections are in particular resulting from HEV genotypes 1 and a couple of. While hepatitis E reasons high mortality among pregnant girls in developing nations, there have been no reviews of this phenomenon from developed nations. Hepatitis E is uncommon among children in developed nations; but, in developing countries, hepatitis E happens in children and, in step with a single record, mortality in very young kids may be high [39]. Large waterborne outbreaks of hepatitis E occur in developing countries where contamination of drinking water occurs[40]; Big outbreaks have now not been suggested from developed countries. However, a few small clusters of hepatitis E related to food borne transmission have come about in Europe and Japan [41]. A study in Russia found that the considerable amount of labor migrants that arrive in Russian Federation have anamnestic antibody response to HEV. The range of these indexes reflect levels of endemicity of particular country the migrants are from. High frequency of anti-HVE IgM detection indicates on present or recent infection. This allows to imply that there is a high risk of HVE importation on the territory of the Russian Federation. The received data indicates on necessity of including screening for acute HEV infection in to the algorithm of routine examination among migrants[42].

Hepatitis A virus (HAV) is transmitted via the fecal-oral route and infection causes acute inflammation of the liver. In developing countries where sanitary conditions are sub optimal, the infection is highly endemic and transmission is via contaminated food, water or the hands. Most infections happen in childhood, are asymptomatic, and larger than 90% of the population by age 10 have immunity [43]. In industrialized, predominantly western nations which might be of low endemicity, spread is typically limited to excessive risk groups together with migrants to HAV endemic nations, contacts of hepatitis A patients and men who've sex with guys (MSM). The case fatality is highest in older age group 2.1% in the ones ≥ 40 years old[44]. Seroprevalence has increased since the mid-1990s due to a burgeoning immigrant population and vaccination campaigns targeting travelers to high-endemic countries, in place since the early 1980s[45]. Symptomatic HAV infection is notifiable and on receipt of a notification, the public health services routinely strains and vaccinates all contacts. For a few years, after the summer season holiday period, a surge in HAV notifications is received in September–October[46]. The majority occur in second generation migrant (SGM) children <16, who are born in the Netherlands, but who contract the infection while on summer holiday in the country of birth of their parents (predominantly Turkey or Morocco).

The endemicity of HBV is low in most developed areas, such as North America, Western and Northern Europe and Australia[47]. The unprecedented rate of migration from high to low prevalence countries may elucidate the increasing incidence of chronic HBV and HCV infections and mortality rates from hepatocellular carcinoma in North America and Western European countries[48][49][50]. The proportion of all immigrants chronically infected with HBV range from 3.7% to 9.7% in the different migrant-receiving countries[51]. Compared with home-grown populations, higher rates of chronic viral hepatitis infections, mortality, and morbidity from hepatocellular carcinoma have been found among ethnic immigrants in the Netherlands[52] UK[53][54]. In the UK, over 95% of new chronic HBV infections occur in immigrant populations[55]. Higher rates of chronic HBV infections were found in immigrant women attending antenatal screening in England[56]. However, immigrants and refugees from intermediate and high prevalence countries are not routinely monitored for HBV and HCV infections, nor is hepatitis B vaccination routinely given in most migrant-receiving countries[57]. Migrants born in intermediate and high HCV prevalence countries who live in low HCV prevalence countries are likely to be at increased risk for HCV due to exposure in their countries of origin[58]. Unlike low HCV prevalence countries where the primary route of transmission is through intravenous drug use, most infections in intermediate and high HCV endemic countries are acquired iatrogenically through contaminated needles, medical procedures or receive of unscreened contaminated blood products[59]. Most migrants are therefore unlikely to be revealed in passing HCV screening programs. Furthermore they have not been identified as a group that should be targeted for HCV screening with the exception of recent UK and Canadian guidelines[58]. This is primarily due to the fact that the HCV burden in this population has not been adequately quantified. There are caveats to the assertion that HDV prevalence is declining. First, developing countries have not always had the same measures of HBV control, and have not shown the same improvements in socioeconomic conditions as have developed countries[60]. Second, HDV prevalence has not decreased in northern Europe. Prevalence in northern Europe and the USA was thought to be low and confined to high-risk groups, such as intravenous drug-users; however, in London, UK, HDV prevalence in people with HBV increased from 2.6% in the 1980s to 8.5% in 2005[61][62]. In Germany, although the prevalence of anti-HDV antibody in those with HBV reduced from 18.6% in 1992 to 6.8% in 1997, from 1999 onwards the rates have increased again to between 8% and 14% [20]. HDV remains prevalent in France. The common thing in these three countries is HDV infection in young people who have migrated from regions of excessive prevalence. Even in Italy the decline in HDV has now reached a plateau [63] and a report has shown a high prevalence of HDV of 17% in non-EU citizens (mainly those from eastern Europe) who are infected with HBV[64]. Third, clustered outbreaks of HDV super infection continue to be reported, notably in Venezuela, Ecuador, Mongolia, and Greenland [65][66] which are similar to those recorded in Samara (Russia), Okinawa (Japan), Central Africa, and the Amazon Basin in the 1980s and 1990s[67]. Thus, while outbreaks still occur

and population migration from endemic countries increases, the threat of HDV infection remains.

5. Documentation of healthy case of immigrants

Yet in many, if not most, European Union (EU) countries, information on the health of migrants is lacking[68];[69], limiting the possibilities for monitoring and improving migrant health, and for conducting comparative studies on inequalities in health and access to healthcare[70]. There are a number of causes for this situation, including the loss of any system for routine gathering of data on the health of migrants. On the other hand to the situation in Australia, Canada, New Zealand and the United States, most countries in Europe do not routinely collect health data by migrant status. While the Netherlands and the United Kingdom have significant experience in conducting population-based surveys that also contain information on migration status or ethnicity, countries such as Belgium, Germany and Spain have only recently started to include such variables in health surveys. There are conceptual and methodological challenges in collecting data on migrant health, such as different definitions or understandings of who constitutes a migrant – and how many migrants, however defined, there are in a given country[71]. Health care utilization data can be an important source of information on migrant health. However, utilization levels cannot be normalized with health needs, as migrants may face barriers in accessing care. In addition, the utilization of health services may not always be properly monitored and recorded, in particular where there are multiple providers spanning the private and public sectors and social project organizations[72];[73]. In 2008–09, registry data on health care utilization that allowed for some identification of migrants at national or regional levels were available in only 11 of the 27 EU member states: Austria, Belgium, Denmark, Finland, Greece, Italy, Luxembourg, the Netherlands, Poland, Slovenia and Sweden[74]. In all 11 countries, utilization data were available for hospital care (although with varying detail), while only a few countries collected data on care in outpatient settings. We noticed, most EU countries do not collect routine data on morbidity and health care utilization by migrants, and those that do use different categorizations and definitions, so that data are not comparable across countries. It is also important to define better those indicators of health directly related to the migration process and to conduct cost-benefit analyses of interventions to improve migrant health. The EU has funded several projects for improving data collection on migrant health, but there is substantial scope for developing migrant health research further, including through increased collaboration at the European level. An overall European vision on the collection of migrant health data, agreed with other major stakeholders such as the IOM and WHO, would help to ensure a more coherent approach to improving the monitoring of migrant health in Europe.

6. Strategies followed by European countries against hepatitis in newly arrived immigrants

There is a study referred to the high incidence of HAV infection in children from developing countries, HAV screening (HAV-IgM) could be indicated on arrival of the migrant pediatric community to low endemic areas and vaccinations should be administered to all susceptible children and assistant nursing staff[75];[76].

In low HBV prevalence immigrant-receiving countries, international migrants from intermediate and high HBV prevalence countries are a large unrecognized risk group for chronic hepatitis B. On July 28th, 2011, the world celebrated the first WHO sponsored World Hepatitis Day. The objective of creating this day was to focus attention on the global health threat of hepatitis and to promote actions to confront it [77].The benefit of screening for chronic HBV in immigrants is that it identifies individuals with asymptomatic chronic HBV infection acquired in their countries of origin, who, if left undetected are at increased risk of progression to HBV-related sequelae, such as liver cirrhosis and HCC. With the timely identification and treatment of infected individuals the risk of developing these long-term sequelae can be reduced[78].This study[79] suggest that targeted screening of immigrants for chronic HBV infection, followed by appropriately timed antiviral therapy is the most cost-effective option to decrease HBV-associated morbidity and mortality in immigrants.

Immigrants explained the prevention of HBV and HCV in various ways Survey studies showed that between 54% and 96% of participants knew that HBV could be prevented through vaccination with no significant difference among the ethnic groups, or wide intra-ethnic variation between studies[80];[81];[82].One Italian study showed that immigrants were significantly less likely than Italian-born patients to receive HBV antiviral therapy[83]

Arguably the most important input contributing to the HCV viraemic pool in many resource-rich countries is provided by HCV-infected immigrants coming from countries traditionally characterized by a high endemicity rate. The proportion of anti-HCV-positive persons among the total infected population in a given country can be as high as one quarter and one third of the total, such as in the case of The Netherlands and Germany, respectively[57].The arrival of potent antivirals, administered in short courses of treatment, without major side effects or contraindications has opened a new era in the management of HCV world wide. The next greatest challenge will be the identification of patients who are unaware of their infection before serious liver-related or extrahepatic complications develop. Thus, more effective screening strategies should be adopted, as was the case recently for the US, with the proposal of a birth cohort screening policy[84].The necessity to adapt this approach to the realities of each single European country, where the patients' age distribution may vary, has been discussed recently and is beyond the scope of this short review. However, birth cohort screening seems cost-effective[85].Identification of barriers to treatment is critical

since studies show that improving sustained virological response (SVR) rates is not enough to improve HCV eradication rates without a concurrent increase in treatment uptake[86].In response to these barriers, various outreach programs have been developed in order to educate, screen, vaccinate and offer treatment to migrants at risk for viral hepatitis[87];[88].Targeted screening is indicated for children who have had medical interventions or who have received blood products in countries where screening of blood is not carried out routinely or where medical equipment is inadequately sterilized. The most important challenge is expensive of HCV treatment. Prices range from US\$ 2 000 in Egypt for 48-weeksof PEG/IFN RBV to as much as US\$84 000 in the US for a single 12-week course of sofosbuvir. At these prices, these treatments will remain unaffordable for most persons who need treatment. A concerted effort is needed to reduce the price of HCV medicines[89].

In some countries children of asylum seekers are eligible for HBV vaccination, and in others adult asylum seekers are also eligible[90];but again, the policies vary considerably and are often so rigid with respect to the legal conditions that have to be met that the right to coverage is not clear to health care providers or potential beneficiaries[91].In other situations regulations concerning refugees as opposed to asylumseekers appear to make it impossible for the latter to benefit from viral hepatitisinitiatives [92].

In a one study in Italy , immigrants are particularly at risk to develop acute hepatitis E after visiting the country of origin and this risk appears to increase with the length of stay in Italy, suggesting a loss of previously acquired immunity[93].

7. Conclusion

Viral hepatitis is a common and growing public health problem worldwide. Liver cirrhosis and HCC caused by chronic HBV and HCV infection are responsible for more than one million deaths annually. Many immigrants have inadequate knowledge of HBV and HCV infections. These findings have implications for public health interventions aimed at stemming the rise in prevalence of HBV and HCV but also that of liver cancer through screening and treatment. That way we conclude that there is a high demand for hepatitis infection screening, detecting , preventing and treating.

References

- [1] U. N. DESA, "United Nations Department of Economic and Social Affairs/Population Division (2009b): World Population Prospects: The 2008 Revision," *Internet http://esa. un. org/unpp (gelesen am 16, 2010).*
- [2] P. Connor, "Number of Refugees to Europe Surges to Record 1.3 Million in 2015," *Pew Res. Center's Glob. Attitudes Proj.*, p. 16, 2016.
- [3] S. Advice, *Systematic review on hepatitis B and C prevalence in the EU / EEA.* .
- [4] M. Rantala and M. J. de Laar, "Surveillance and epidemiology of hepatitis B and C in Europe-a review.," *Euro Surveill. Bull. Eur. sur les Mal. Transm. Eur.*

- Commun. Dis. Bull.*, vol. 13, no. 21, pp. 717–727, 2008.
- [5] K. Mohd Hanafiah, J. Groeger, A. D. Flaxman, and S. T. Wiersma, “Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence,” *Hepatology*, vol. 57, no. 4, pp. 1333–1342, 2013.
- [6] K. Beebejaun *et al.*, “Outbreak of hepatitis A associated with men who have sex with men (MSM), England, July 2016 to January 2017,” *Euro Surveill*, vol. 22, no. 5, p. 30454, 2017.
- [7] M. Herremans *et al.*, “Swine-like hepatitis E viruses are a cause of unexplained hepatitis in the Netherlands,” *J. Viral Hepat.*, vol. 14, no. 2, pp. 140–146, 2007.
- [8] K. Waar, M. Herremans, H. Vennema, M. P. G. Koopmans, and C. A. Benne, “Hepatitis E is a cause of unexplained hepatitis in The Netherlands,” *J. Clin. Virol.*, vol. 33, no. 2, pp. 145–149, 2005.
- [9] M. Fogeda, A. Avellón, and J. M. Echevarria, “Prevalence of specific antibody to hepatitis E virus in the general population of the community of Madrid, Spain,” *J. Med. Virol.*, vol. 84, no. 1, pp. 71–74, 2012.
- [10] M. Bura, M. Michalak, M. Chojnicki, A. Czajka, A. Kowala-Piaskowska, and I. Mozer-Lisewska, “Seroprevalence of anti-HEV IgG in 182 Polish patients,” *Postep. Hig. Med. Dosw.*, vol. 69, pp. 320–326, 2015.
- [11] S. Sauleda *et al.*, “Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain),” *Transfusion*, vol. 55, no. 5, pp. 972–979, 2015.
- [12] A. Avellon, L. Morago, M. del Carmen, M. Munoz, and J.-M. Echevarria, “Comparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection,” *J. Med. Virol.*, vol. 87, no. 11, pp. 1934–1939, 2015.
- [13] S. Ijaz, A. J. Vyse, D. Morgan, R. G. Pebody, R. S. Tedder, and D. Brown, “Indigenous hepatitis E virus infection in England: more common than it seems,” *J. Clin. Virol.*, vol. 44, no. 4, pp. 272–276, 2009.
- [14] G. Scotto *et al.*, “Hepatitis E virus co-infection in HIV-infected patients in Foggia and Naples in southern Italy,” *Infect. Dis. (Auckl.)*, vol. 47, no. 10, pp. 707–713, 2015.
- [15] M. Bouwknegt *et al.*, “Bayesian estimation of hepatitis E virus seroprevalence for populations with different exposure levels to swine in The Netherlands,” *Epidemiol. Infect.*, vol. 136, no. 4, pp. 567–576, 2008.
- [16] B. Olsen, D. Axelsson-Olsson, A. Thelin, and O. Weiland, “Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls,” *Scand. J. Infect. Dis.*, vol. 38, no. 1, pp. 55–58, 2006.
- [17] M. Faber, J. J. Wenzel, W. Jilg, M. Thamm, M. Höhle, and K. Stark, “Hepatitis E virus seroprevalence among adults, Germany,” 2012.
- [18] M. Rapicetta *et al.*, “Seroprevalence and anti-HEV persistence in the general population of the Republic of San Marino,” *J. Med. Virol.*, vol. 58, no. 1, pp. 49–53, 1999.
- [19] M. Buti *et al.*, “Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain,” *Clin. Vaccine Immunol.*, vol. 13, no. 12, pp. 1328–1332, 2006.
- [20] H. Wedemeyer and M. P. Manns, “Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead,” *Nat. Rev. Gastroenterol. Hepatol.*, vol. 7, no. 1, pp. 31–40, 2010.
- [21] M. Rizzetto, A. Ponzetto, and I. Forzani, “Hepatitis delta virus as a global health problem,” *Vaccine*, vol. 8, pp. S10–S14, 1990.
- [22] G. A. Popescu *et al.*, “Epidemiology of hepatitis D in patients infected with hepatitis B virus in bucharest: A cross-sectional study,” *J. Med. Virol.*, vol. 85, no. 5, pp. 769–774, 2013.
- [23] P. Rivas *et al.*, “Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in Spain,” *Am. J. Trop. Med. Hyg.*, vol. 88, no. 4, pp. 789–794, 2013.
- [24] *The EU in the world 2016 edition*. 2016.
- [25] N. Sa and K. C. Earhart, “HIV, Hepatitis C, and Hepatitis B Infections and Associated Risk Behavior in Injection Drug Users,” vol. 13, no. 9, pp. 1327–1331, 2007.
- [26] H. Bashour and G. Muhjazi, “Hepatitis B and C in the Syrian Arab Republic: a review.”
- [27] A. Al-Rubaye, Z. Tariq, and L. Alrubaiy, “Prevalence of hepatitis B seromarkers and hepatitis C antibodies in blood donors in Basra, Iraq,” *BMJ open Gastroenterol.*, vol. 3, p. e000067, 2016.
- [28] A. S. Al-Naaimi *et al.*, “Predicting acute viral hepatitis serum markers (A and E) in patients with suspected acute viral hepatitis attending primary health care centers in Baghdad: a one year cross-sectional study,” *Glob. J. Health Sci.*, vol. 4, no. 5, pp. 172–83, 2012.
- [29] M. Chironna, C. Germinario, P. L. Lopalco, F. Carrozzini, and M. Quarto, “Prevalence of hepatitis virus infections in Kosovar refugees,” *Int. J. Infect. Dis.*, vol. 5, no. 4, pp. 209–213, 2001.
- [30] S. Ashraf and A. Ahmad, “Asian Pacific Journal of Tropical Biomedicine,” *Asian Pac. J. Trop. Biomed.*, vol. 5, no. 3, pp. 190–191, 2015.
- [31] S. A. Ali, R. M. J. Donahue, H. Qureshi, and S. H. Vermund, “Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors,” *Int. J. Infect. Dis.*, vol. 13, no. 1, pp. 9–19, 2009.
- [32] H. Ghebrekidan, S. Cox, B. Wahren, and M. Grandien, “Prevalence of infection with HIV, hepatitis B and C viruses, in four high risk groups in Eritrea,” *Clin. Diagn. Virol.*, vol. 9, no. 1, pp. 29–35, 1998.
- [33] A. Schweitzer, J. Horn, R. T. Mikolajczyk, G. Krause, and J. J. Ott, “Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013,” *Lancet*, vol. 386, no. 10003, pp. 1546–1555, 2015.
- [34] B. M. Musa, S. Bussell, M. M. Borodo, A. A. Samaila, and O. L. Femi, “Prevalence of hepatitis B virus infection in Nigeria, 2000–2013: a systematic review and meta-analysis,” *Niger. J. Clin. Pract.*, vol. 18, no. 2, pp. 163–172, 2015.
- [35] S. M. Alavian, F. Fallahian, and K. B. Lankarani, “The changing epidemiology of viral hepatitis B in Iran,” *J. Gastrointest. Liver Dis.*, vol. 16, no. 4, p. 403, 2007.
- [36] R. Taherkhani and F. Farshadpour, “Epidemiology of hepatitis C virus in Iran,” *World J. Gastroenterol. WJG*, vol. 21, no. 38, p. 10790, 2015.

- [37] D. B. Rein, G. A. Stevens, J. Theaker, J. S. Wittenborn, and S. T. Wiersma, "The global burden of hepatitis E virus genotypes 1 and 2 in 2005," *Hepatology*, vol. 55, no. 4, pp. 988–997, 2012.
- [38] N. Kamar *et al.*, "Hepatitis E virus and chronic hepatitis in organ-transplant recipients," *N. Engl. J. Med.*, vol. 358, no. 8, pp. 811–817, 2008.
- [39] M. B. Sharapov *et al.*, "Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data," *BMC Infect. Dis.*, vol. 9, no. 1, p. 35, 2009.
- [40] E. S. Gurley *et al.*, "Estimating the burden of maternal and neonatal deaths associated with jaundice in Bangladesh: possible role of hepatitis E infection," *Am. J. Public Health*, vol. 102, no. 12, pp. 2248–2254, 2012.
- [41] H. Matsuda, K. Okada, K. Takahashi, and S. Mishiro, "Severe hepatitis E virus infection after ingestion of uncooked liver from a wild boar," *J. Infect. Dis.*, vol. 188, no. 6, p. 944, 2003.
- [42] Alsalikh N.D., Sichev D.A., Potemkin I.A., Polyakov A.D., Malinnikova E.Yu., Kyuregyan K.K. and M. M.I., "Frequency of detection of hepatitis virus E infection markers among labor migrants arriving in Russian Federation," *FAR EAST J. Infect. Dis.*, vol. 5c, pp. 27–31, 2016.
- [43] K. H. Jacobsen and S. T. Wiersma, "Hepatitis A virus seroprevalence by age and world region, 1990 and 2005," *Vaccine*, vol. 28, no. 41, pp. 6653–6657, 2010.
- [44] J. Whelan, G. Sonder, and A. van den Hoek, "Declining incidence of hepatitis A in Amsterdam (The Netherlands), 1996-2011: Second generation migrants still an important risk group for virus importation," *Vaccine*, vol. 31, no. 14, pp. 1806–1811, 2013.
- [45] L. Verhoef *et al.*, "Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995–1996 and 2006–2007," *Epidemiol. Infect.*, vol. 139, no. 8, pp. 1172–1180, 2011.
- [46] F. Termorshuizen, J. W. Dorigo-Zetsma, H. E. De Melker, M. A. E. CONYN-VAN SPAENDONCK, and others, "The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey," *Epidemiol. Infect.*, vol. 124, no. 3, pp. 459–466, 2000.
- [47] J. A. Owiti, T. Greenhalgh, L. Sweeney, G. R. Foster, and K. S. Bhui, "Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review," *BMC Public Health*, vol. 15, no. 1, p. 151, 2015.
- [48] J. J. Chu *et al.*, "Changing epidemiology of Hepatitis B and migration—a comparison of six Northern and North-Western European countries," *Eur. J. Public Health*, vol. 23, no. 4, pp. 642–647, 2013.
- [49] S. McDermott *et al.*, "Cancer incidence among Canadian immigrants, 1980–1998: results from a national cohort study," *J. Immigr. Minor. Heal.*, vol. 13, no. 1, pp. 15–26, 2011.
- [50] K. A. McGlynn and W. T. London, "The global epidemiology of hepatocellular carcinoma: present and future," *Clin. Liver Dis.*, vol. 15, no. 2, pp. 223–243, 2011.
- [51] C. Rossi *et al.*, "Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis," *PLoS One*, vol. 7, no. 9, p. e44611, 2012.
- [52] A. T. Urbanus *et al.*, "Hepatitis C in the general population of various ethnic origins living in the Netherlands: Should non-Western migrants be screened?," *J. Hepatol.*, vol. 55, no. 6, pp. 1207–1214, 2011.
- [53] R. J. Harris *et al.*, "Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis," *Eur. J. Public Health*, p. ckr083, 2011.
- [54] A. G. Mann, C. L. Trotter, M. Adekoyejo Balogun, and M. E. Ramsay, "Hepatitis C in ethnic minority populations in England," *J. Viral Hepat.*, vol. 15, no. 6, pp. 421–426, 2008.
- [55] S. Bhattacharya *et al.*, "Ante-natal screening and post-natal follow-up of hepatitis B in the West Midlands of England," *Qjm*, vol. 101, no. 4, pp. 307–312, 2008.
- [56] J. K. Dyson *et al.*, "Hepatitis B in pregnancy. Frontline Gastroenterol 2014; 5: 111-117; PMID: 24683447." 2014.
- [57] M. van de Laar, I. Veldhuijzen, and S. Hahn, "Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies," *Stock. ECDC*, vol. 56, 2010.
- [58] C. Greenaway *et al.*, "Hepatitis C: Evidencebased clinical guidelines for immigrants and refugees," *Can Med Assoc J*, vol. 183, no. 12, pp. E861–E4, 2011.
- [59] B. Hajarizadeh, J. Grebely, and G. J. Dore, "Epidemiology and natural history of HCV infection," *Nat. Rev. Gastroenterol. Hepatol.*, vol. 10, no. 9, pp. 553–562, 2013.
- [60] S. A. Hughes, H. Wedemeyer, and P. M. Harrison, "Hepatitis delta virus," *Lancet*, vol. 378, no. 9785, pp. 73–85, 2011.
- [61] H. M. Smith, G. J. Alexander, G. Webb, T. McManus, I. G. McFarlane, and R. Williams, "Hepatitis B and delta virus infection among 'at risk' populations in south east London.," *J. Epidemiol. Community Health*, vol. 46, no. 2, pp. 144–147, 1992.
- [62] T. J. S. Cross *et al.*, "The increasing prevalence of hepatitis delta virus (HDV) infection in South London," *J. Med. Virol.*, vol. 80, no. 2, pp. 277–282, 2008.
- [63] G. B. Gaeta, T. Stroffolini, A. Smedile, G. Niro, and A. Mele, "Hepatitis delta in Europe: vanishing or refreshing?," *Hepatology*, vol. 46, no. 4, pp. 1312–1313, 2007.
- [64] P. Piccolo *et al.*, "Patterns of chronic hepatitis B in Central Italy: a cross-sectional study," *Eur. J. Public Health*, vol. 20, no. 6, pp. 711–713, 2010.
- [65] T. Nakano *et al.*, "Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela," *J. Gen. Virol.*, vol. 82, no. 9, pp. 2183–2189, 2001.
- [66] S. R. Manock *et al.*, "An outbreak of fulminant hepatitis delta in the Waorani, an indigenous people of the Amazon basin of Ecuador.," *Am. J. Trop. Med. Hyg.*, vol. 63, no. 3, pp. 209–213, 2000.
- [67] E. Flodgren *et al.*, "Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains," *J. Clin. Microbiol.*, vol. 38, no. 9, pp. 3311–3316, 2000.
- [68] S. B. Rafnsson and R. S. Bhopal, "Migrant and ethnic health research: report on the European Public Health Association Conference 2007," *Public Health*, vol. 122,

- no. 5, pp. 532–534, 2008.
- [69] B. Padilla and M. J. Pereira, “Health and Migration in the EU: Building a Shared Vision for Action. Background papers.” 2007.
- [70] A. Kraler and D. Reichel, “Statistics on migration, integration and discrimination in Europe,” *PROMINSTAT Final report. Brussels Eur. Comm.*, 2010.
- [71] N. C. Aung, B. Rechel, and P. Odermatt, “Access to and utilisation of GP services among Burmese migrants in London: a cross-sectional descriptive study,” *BMC Health Serv. Res.*, vol. 10, no. 1, p. 285, 2010.
- [72] J. Mindell, E. Klodawski, J. Fitzpatrick, N. Malhotra, M. McKee, and C. Sanderson, “The impact of private-sector provision on equitable utilisation of coronary revascularisation in London,” *Heart*, vol. 94, no. 8, pp. 1008–1011, 2008.
- [73] W. H. Organization and others, “Health of migrants: the way forward. Report of a global consultation, Madrid, Spain, 3-5 March, 2010.,” *Heal. migrants W. forward. Rep. a Glob. Consult. Madrid, Spain, 3-5 March, 2010.*, 2010.
- [74] S. S. Nielsen, A. Krasnik, and A. Rosano, “Registry data for cross-country comparisons of migrants’ healthcare utilization in the EU: a survey study of availability and content,” *BMC Health Serv. Res.*, vol. 9, no. 1, p. 210, 2009.
- [75] F. Castelli *et al.*, “Pediatric Migration and Hepatitis A in Host Population,” pp. 204–206, 1999.
- [76] S. Faillon *et al.*, “Impact of travel on the seroprevalence of hepatitis A in children,” *J. Clin. Virol.*, vol. 56, no. 1, pp. 46–51, 2013.
- [77] J. W. Ward, F. M. Averhoff, and H. K. Koh, “World Hepatitis Day: a new era for hepatitis control,” *Lancet*, vol. 378, no. 9791, p. 552, 2011.
- [78] M. J. Tong *et al.*, “The management of chronic hepatitis B in Asian Americans,” *Dig. Dis. Sci.*, vol. 56, no. 11, pp. 3143–3162, 2011.
- [79] C. Rossi, K. Schwartzman, O. Oxlade, M. B. Klein, and C. Greenaway, “Hepatitis B Screening and Vaccination Strategies for Newly Arrived Adult Canadian Immigrants and Refugees: A Cost-Effectiveness Analysis,” *PLoS One*, vol. 8, no. 10, pp. 1–9, 2013.
- [80] M. Xiong, R. H. N. Nguyen, L. Strayer, S. Chanthanouvong, and J.-M. Yuan, “Knowledge and behaviors toward hepatitis B and the Hepatitis B Vaccine in the Laotian community in Minnesota,” *J. Immigr. Minor. Heal.*, vol. 15, no. 4, pp. 771–778, 2013.
- [81] G. X. Ma *et al.*, “Knowledge, attitudes, and behaviors of hepatitis B screening and vaccination and liver cancer risks among Vietnamese Americans,” *J. Health Care Poor Underserved*, vol. 18, no. 1, pp. 62–73, 2007.
- [82] D. Li, T. Tang, M. Patterson, M. Ho, J. Heathcote, and H. Shah, “The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons,” *Can. J. Gastroenterol. Hepatol.*, vol. 26, no. 9, pp. 597–602, 2012.
- [83] G. Antonucci *et al.*, “Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy,” *J. Viral Hepat.*, vol. 19, no. 12, pp. 881–889, 2012.
- [84] B. D. Smith *et al.*, “Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965,” *Morb. Mortal. Wkly. Rep. Recomm. Reports*, vol. 61, no. 4, pp. 1–32, 2012.
- [85] L. J. McGarry *et al.*, “Economic model of a birth cohort screening program for hepatitis C virus,” *Hepatology*, vol. 55, no. 5, pp. 1344–1355, 2012.
- [86] D. L. Thomas, “Curing hepatitis C with pills: a step toward global control,” *Lancet*, vol. 376, no. 9751, p. 1441, 2010.
- [87] P. V. Perumalswami *et al.*, “Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities,” *J. Hepatol.*, vol. 58, no. 5, pp. 890–897, 2013.
- [88] C. Richter *et al.*, “Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands,” *Epidemiol. Infect.*, vol. 142, no. 10, pp. 2140–2146, 2014.
- [89] World Health Organization, “Guidelines for the screening, care and treatment of persons with hepatitis C infection,” *Guidelines*, no. April, p. 124, 2014.
- [90] M. Norredam, A. Mygind, and A. Krasnik, “Access to health care for asylum seekers in the European Union—a comparative study of country policies,” *Eur. J. Public Health*, vol. 16, no. 3, pp. 285–289, 2006.
- [91] L. Vuorenkoski, P. Mladovsky, and E. Mossialos, “Finland: Health system review,” 2008.
- [92] M. Strandberg-Larsen, M. B. Nielsen, S. Vallgård, A. Krasnik, K. Vrangbæk, and E. Mossialos, “Health systems in transition,” *Health (Irvine. Calif.)*, vol. 14, no. 2, pp. 1–164, 2007.
- [93] V. Chandra, S. Taneja, M. Kalia, and S. Jameel, “Molecular biology and pathogenesis of hepatitis E virus,” *J. Biosci.*, vol. 33, no. 4, pp. 451–464, 2008.